Back to search

Ireland· IE-PA-EU/1/17/1235/004-005

Zejula 100 mg Film-coated tablet

A niraparib product containing niraparid tosylate monohydrate, registered in Ireland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 14 of our 19 countries.

ATC L01XK02

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedZejula 100 mg Film-coated tabletATCL01XK02REGISTER NO.IE-PA-EU/1/17/1235/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Niraparib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XK02 (niraparib), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Niraparib · ATC L01XK02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of niraparib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Niraparib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$276.18
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Niraparid tosylate monohydrate
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Ireland (IE)
ATC code
L01XK02
ATC class
Niraparib
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1235/004-005

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

405 interactions on record for niraparib.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Niraparib · interactions on record

405 records

  • 29 severe
  • 376 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • RolapitantA04AD14moderate
  • LonafarnibA16AX20moderate
  • DicoumarolB01AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ff0d1152-1a85-4b9d-bd55-079b4c2e1fa9
GET /v1/drugs/ff0d1152-1a85-4b9d-bd55-079b4c2e1fa9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XK02"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1235/004-005",
  "substances": [
    "Niraparid tosylate monohydrate"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "30/05/2022",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about niraparib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.